Salirasib

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Salirasib(Ki=2.6 μM), an effective competitive prenylated protein methyltransferase (PPMTase) inhibitor, inhibits Ras methylation with potential antineoplastic activity.

Salirasib is a salicylic acid derivative with potential antineoplastic activity. Salirasib dislodges all Ras isoforms from their membrane-anchoring sites, thereby preventing activation of RAS signaling cascades that mediated cell proliferation, differentiation, and senescence. RAS signaling is believed to be abnormally activated in one-third of human cancers, including cancers of the pancreas, colon, lung and breast.

Salirasib; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; FTS

Others

Other Targets

PPMTase

Cancer

——

162520-00-5

358.54

C22H30O2S

98%

DMSO : ≥ 50 mg/mL 139.45 mM; H2O : < 0.1 mg/mL

C(=O)(c1c(SC/C=C(\C)/CC/C=C(\C)/CCC=C(C)C)cccc1)O

2-(((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)thio)benzoic acid

(-20℃)

With Ice Pack

≥ 2 years